Article Versions Notes

Garciaz S, Hospital M-A, Alary A-S, Saillard C, Hicheri Y, Mohty B, Rey J, D’Incan E, Charbonnier A, Villetard F, et al. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers. 2022; 14(8):2025. https://doi.org/10.3390/cancers14082025

Garciaz, Sylvain, Marie-Anne Hospital, Anne-Sophie Alary, Colombe Saillard, Yosr Hicheri, Bilal Mohty, Jérôme Rey, Evelyne D’Incan, Aude Charbonnier, Ferdinand Villetard, and et al. 2022. "Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients" Cancers 14, no. 8: 2025. https://doi.org/10.3390/cancers14082025

Garciaz, S., Hospital, M.-A., Alary, A.-S., Saillard, C., Hicheri, Y., Mohty, B., Rey, J., D’Incan, E., Charbonnier, A., Villetard, F., Maisano, V., Lombardi, L., Ittel, A., Mozziconacci, M.-J., Gelsi-Boyer, V., & Vey, N. (2022). Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers, 14(8), 2025. https://doi.org/10.3390/cancers14082025